SC
RARE icon

Stephens Consulting’s Ultragenyx Pharmaceutical RARE Stock Holding History

Stephens Consulting’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1
Closed -$37 – 979
2025
Q2 		$37 Buy
+1
New +$36 ﹤0.01% 1139

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Stephens Consulting's RARE Position: Q3 2025 in Review

Stephens Consulting sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2025, closing a stake of 1 share — an estimated $37 sold.

Stephens Consulting first reported a position in RARE in Q2 2025 and held it in 1 quarter. The position peaked at $37 in Q2 2025. 302 funds tracked by Wall St. Rank hold RARE as of Q3 2025.

  • Stephens Consulting reported no remaining Ultragenyx Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • Stephens Consulting sold 1 Ultragenyx Pharmaceutical share in Q3 2025, an estimated $37.
  • Stephens Consulting first reported a position in Ultragenyx Pharmaceutical in Q2 2025 and held it in 1 quarter.
  • Stephens Consulting's Ultragenyx Pharmaceutical position peaked at $37 in Q2 2025.
  • 302 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2025.

Based on Stephens Consulting's 13F filing for Q3 2025, filed 15 Oct 2025.